Listed

Edwards Lifesciences Corp: Form 10-Q for the period ended Mar 31, 2021

Filed with the SEC on Apr 28, 2021 and accepted by EDGAR at Apr 28, 2021, 16:09 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-01-01 to 2021-03-31$1.22bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2021-01-01 to 2021-03-31$293.4mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2021-01-01 to 2021-03-31$923.2mus-gaap:GrossProfit
Research and development3 months2021-01-01 to 2021-03-31$207.0mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2021-01-01 to 2021-03-31$330.8mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2021-01-01 to 2021-03-31$383.5mus-gaap:OperatingIncomeLoss
Income tax3 months2021-01-01 to 2021-03-31$51.1mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-01-01 to 2021-03-31$338.2mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2021-01-01 to 2021-03-31$0.54us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-01-01 to 2021-03-31$0.54us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-01-01 to 2021-03-31631,300,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2021-01-01 to 2021-03-31$300.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2021-01-01 to 2021-03-31$106.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases3 months2021-01-01 to 2021-03-31$302.6mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2021-03-31$1.17bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-03-31$3.07bnus-gaap:AssetsCurrent
Total assetsAt period end2021-03-31$7.21bnus-gaap:Assets
Current liabilitiesAt period end2021-03-31$799.0mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2021-03-31$595.2mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2021-03-31$4.66bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001099800-21-000012. Last ingested by Listed: Nov 15, 2026, 03:19 ET. Listed shows no prices and gives no investment advice.